Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Kristina Lohmann"'
Autor:
Christoph Sarrazin, Christoph Boesecke, Solmaz Golsabahi‐Broclawski, Gero Moog, Francesco Negro, Carmina Silaidos, Polly Patel, Kristina Lohmann, Christoph D. Spinner, Stephan Walcher, Heiner Wedemeyer, Marcus‐Alexander Wörns
Publikováno v:
Health Science Reports, Vol 4, Iss 2, Pp n/a-n/a (2021)
Abstract Hepatitis C virus (HCV) affects over 70 million people globally, with an estimated 399 000 HCV‐related deaths in 2016. The World Health Organization (WHO) has set a goal to eliminate HCV by 2030. Despite the availability of direct‐acting
Externí odkaz:
https://doaj.org/article/f0f916e9026147a38840fd329d60ae58
Autor:
Markus Cornberg, Albrecht Stoehr, Uwe Naumann, Gerlinde Teuber, Hartwig Klinker, Thomas Lutz, Hjördis Möller, Dennis Hidde, Kristina Lohmann, Karl-Georg Simon
Publikováno v:
Viruses, Vol 14, Iss 7, p 1541 (2022)
Using data from the German Hepatitis C-Registry (Deutsche Hepatitis C-Register, DHC-R), we report the real-world safety and effectiveness of glecaprevir/pibrentasvir (GLE/PIB) treatment and its impact on patient-reported outcomes (PROs) in underserve
Externí odkaz:
https://doaj.org/article/532c9a6f11bb4770b3725443cac8deaa
Autor:
Kristina Lohmann, Dietrich Hüppe, Dennis Hidde, Stefan Mauss, Hartwig Klinker, Albrecht Stoehr, Mark Bondin, Peter Buggisch, Gerlinde Teuber, Heiner Wedemeyer
Publikováno v:
Journal of Viral Hepatitis. 28:1474-1483
The number of patients diagnosed with hepatitis C virus (HCV) is markedly higher than the number initiating treatment indicating gaps in the care cascade, likely centred around reaching at-risk populations. Understanding changing characteristics of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8f1ad8db276188a703c956cc0382d0
https://doi.org/10.1111/jvh.13586
https://doi.org/10.1111/jvh.13586
Autor:
Stefan Zeuzem, U Naumann, Mark Bondin, Kristina Lohmann, Bettina Koenig, Markus Cornberg, Hartwig Klinker, Thomas Berg, Martin Rössle
Publikováno v:
Liver International. 41:1518-1522
Glecaprevir/pibrentasvir, a pangenotypic, direct-acting antiviral combination approved for chronic hepatitis C virus treatment, has limited real-world evidence supporting 8-week therapy in compensated cirrhosis. We investigated effectiveness and safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52395ca4faa66d98caf302164702e173
https://doi.org/10.1111/liv.14937
https://doi.org/10.1111/liv.14937
Autor:
Pietro Lampertico, Heiner Wedemeyer, Marcello Persico, Fiona Marra, Kristina Lohmann, Steven L. Flamm, Mark Bondin, Steven E Marx, Stephen T. Barclay, Zhen Zhen Zhang, Pamela S. Belperio, Stefan Mauss
Publikováno v:
Advances in Therapy
ADVANCES IN THERAPY
ADVANCES IN THERAPY
Introduction: More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84815f3c681f3412b431006e0fa7968e
http://europepmc.org/articles/PMC7547986
http://europepmc.org/articles/PMC7547986
Autor:
Heiner Wedemeyer, Stefan Mauss, Bettina König, Albrecht Stoehr, Ansgar P. Rieke, Peter Erren, Tim Zimmermann, U Naumann, Kristina Lohmann
Publikováno v:
Liver international : official journal of the International Association for the Study of the LiverREFERENCES. 41(5)
Glecaprevir/pibrentasvir is a pangenotypic direct-acting antiviral regimen approved for treating chronic hepatitis C virus. Real-world use of protease-inhibitor-containing regimens requires further evaluation in patients with cirrhosis. We evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96653a202ccd98fe1999845ef37c1906
https://pubmed.ncbi.nlm.nih.gov/33592123
https://pubmed.ncbi.nlm.nih.gov/33592123
Publikováno v:
DGVS Digital: BEST OF DGVS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c8933dae8b1710783dcb504cc884cb7
https://doi.org/10.1055/s-0040-1716171
https://doi.org/10.1055/s-0040-1716171
Autor:
Pietro Lampertico, Pamela S. Belperio, Fiona Marra, Steven E Marx, Kristina Lohmann, Stephen T. Barclay, Stefan Mauss, Mark Bondin, Heiner Wedemeyer, Zhen Zhen Zhang, Steven L. Flamm, Marcello Persico
Publikováno v:
Advances in Therapy
More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compensated cirrhosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4732b17186dcaa2d7fa1380b8215a55e
https://doi.org/10.1007/s12325-020-01482-z
https://doi.org/10.1007/s12325-020-01482-z
Autor:
T Lutz, M Cornberg, KG Simon, Andreas Pangerl, A Stoehr, B König, W Schiffelholz, H Kliniker, N Qurishi, U Naumann, Kristina Lohmann
Publikováno v:
Zeitschrift für Gastroenterologie.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf14a8ebfec6c446166ebf9a0c9e1218
https://doi.org/10.1055/s-0039-1695336
https://doi.org/10.1055/s-0039-1695336
Autor:
Christine John, Thomas Berg, Bettina König, Albrecht Stoehr, Andreas Pangerl, Gerlinde Teuber, U Naumann, Kristina Lohmann, W Schiffelholz, Christoph Sick, Stefan Mauss, Claus Niederau
BACKGROUND Glecaprevir/pibrentasvir is a pangenotypic direct-acting antiviral regimen approved for treating adults chronically infected with hepatitis C virus (HCV). There are limited real-world data on glecaprevir/pibrentasvir to date. AIM To evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b64e159e283fbb02e30c0decd438ef40
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85062940069
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85062940069
